Gastric Cancer Targeted Therapy in China: 2026 Drug Price & Access Guide

• Drug Costs: Domestic PD-1 inhibitors cost around $150 per dose, saving self-pay patients up to 90% compared to US prices.
• Exclusive Access: Novel drugs like the HER2 ADC Disitamab Vedotin (RC48) and Claudin18.2 CAR-T therapies are available in China but unapproved in the US.
• Biomarker Focus: Top Chinese centers mandate comprehensive molecular testing (HER2, Claudin18.2, PD-L1) to match patients with precision therapies.
• Outpatient Logistics: Renting a serviced apartment near the oncology center is critical for managing systemic therapy cycles and monitoring side effects.

Gastric cancer incidence is historically highest in East Asia, a reality that has driven Chinese medical institutions to develop rapid pharmaceutical innovation and unparalleled clinical trial volume. For international patients researching medical options in 2026, traveling to China offers a distinct dual advantage: massive cost reductions on standard systemic therapies and immediate access to novel, exclusive drugs that remain unavailable in Western healthcare systems.

Navigating cross-border oncology care requires precise planning. This guide outlines the practical steps for international patients comparing drug prices, evaluating clinical trial eligibility, and preparing for the unique logistical requirements of undergoing targeted gastric cancer therapy in China.

Patients travel to China to access a combination of dramatically lower drug prices and exclusive next-generation therapies. This route is particularly valuable for self-pay patients seeking advanced targeted treatments who have exhausted standard lines of therapy in their home countries.

Gastric cancer treatment relies heavily on biomarker-driven therapies. In the United States, patients without comprehensive insurance coverage face overwhelming out-of-pocket costs for standard immunotherapies. In contrast, China's centralized procurement system and robust domestic pharmaceutical industry have driven the cost of world-class oncology drugs down to a fraction of global averages.

Beyond cost, clinical access is a primary motivator. Chinese research hospitals—particularly leading institutions in Guangzhou, Beijing, and Shanghai—are at the global forefront of specific therapeutic pathways, notably Claudin18.2 (CLDN18.2) and HER2-targeted treatments.

Gastric cancer medications in China typically cost 10% to 30% of US prices. Domestic immunotherapies and targeted drugs offer massive savings for international self-pay patients without compromising clinical efficacy.

Late-stage gastric cancer treatment costs are predominantly driven by systemic medications. In China, foreign patients do not qualify for national health insurance reimbursement, but they still benefit from the heavily negotiated "network listing prices" (挂网价) at public hospitals.

Before any drug is prescribed, top Chinese hospitals mandate comprehensive molecular testing for HER2, PD-L1 (CPS score), MSI-H/dMMR, and Claudin18.2. This ensures targeted precision and avoids wasted expenditure on ineffective drugs.

Immunotherapy Price Gaps The cost difference in PD-1 inhibitors is staggering, a trend further detailed in our 2026 melanoma drug price guide. Domestic PD-1 drugs like Sintilimab and Tislelizumab are widely used as first-line treatments for gastric cancer in China, costing approximately 1,000 to 1,250 RMB (about $150 USD) per dose. By comparison, the US wholesale acquisition cost for similar drugs like Keytruda is nearly $11,795 per dose. Even imported Keytruda is significantly cheaper in China, priced at around $2,490 USD.

Targeted Therapy Savings For HER2-positive patients, Trastuzumab (Herceptin) and its high-quality biosimilars are available at a fraction of US costs due to national volume-based procurement. Similar pricing dynamics apply to chemotherapy regimens (FLOT, SOX, XELOX), where domestic manufacturing keeps per-cycle costs exceptionally low.

China leads in several novel therapeutic pathways, offering drugs like the HER2-targeted ADC Disitamab Vedotin (RC48) and Claudin18.2 CAR-T cell therapies that remain unapproved and unavailable in the United States.

For many international patients, the decision to travel is not just about saving money—it is about accessing treatments that do not exist at home.

Disitamab Vedotin (RC48) This is a Chinese-developed antibody-drug conjugate (ADC) specifically targeting HER2-expressing gastric cancers. While it has shown strong efficacy and is fully approved and accessible in China, it is not yet approved by the US FDA, making it an exclusive option for patients traveling to Chinese hospitals.

The Claudin18.2 Frontier Gastric cancer is the primary battlefield for CLDN18.2 targeted therapies. While Zolbetuximab (the first CLDN18.2 monoclonal antibody) is available globally, China is aggressively advancing the next generation of treatment: CLDN18.2 CAR-T cell therapies (such as satri-cel). Chinese research institutions dominate the global landscape for solid tumor CAR-T trials, offering compassionate use or trial enrollment for eligible late-stage patients.

For a broader understanding of how China's pharmaceutical pricing impacts other oncology fields, you can review our Lung Cancer Treatment in China: 2026 Drug Price & Care Guide.

Targeted therapy is only as effective as the diagnostic testing behind it. Top Chinese oncology centers utilize advanced Next-Generation Sequencing (NGS) to profile gastric tumors, ensuring patients are matched with the exact molecule suited to their cancer's genetic signature.

Because gastric cancer is highly prevalent in East Asia, Chinese oncologists possess unmatched clinical experience in interpreting complex biomarker profiles. Major cancer centers in cities like Guangzhou and Shanghai process thousands of gastric tumor samples annually. This high throughput reduces testing turnaround times and ensures high accuracy for emerging biomarkers like Claudin18.2, which requires highly specific immunohistochemistry (IHC) assays.

Accessing Clinical Trials For patients who have exhausted standard therapies, China's clinical trial ecosystem offers a lifeline. Institutions such as the Sun Yat-sen University Cancer Center in Guangzhou frequently lead global multi-center trials for novel ADCs and bispecific antibodies. International patients with properly translated medical records can often be evaluated for trial eligibility, potentially gaining access to tomorrow's breakthrough drugs at little to no cost for the medication itself.

The total cost depends on the specific drug regimen and the duration of therapy. Late-stage systemic therapy averages $30,000–$50,000 annually, representing a fraction of US out-of-pocket expenses.

Understanding the financial scope requires looking at the specific pharmaceutical pathway required for your diagnosis.

• First-Line Immunotherapy + Chemo: A standard regimen combining a domestic PD-1 inhibitor (e.g., Sintilimab) with chemotherapy (SOX or XELOX) typically costs between 3,000 and 5,000 RMB ($400–$700 USD) per cycle.
• HER2-Targeted ADCs: Treatment with exclusive drugs like RC48 (Disitamab Vedotin) costs significantly less than Western ADCs, though exact out-of-pocket pricing depends on dosage and patient weight.
• CAR-T Cell Therapy: If a patient qualifies for a Claudin18.2 CAR-T clinical trial, the engineered cells are often provided free of charge, though patients must cover the costs of hospitalization, pre-conditioning chemotherapy, and management of potential side effects like Cytokine Release Syndrome (CRS), which can range from $10,000 to $20,000 USD.
• Peritoneal Metastasis: China routinely utilizes Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal spread, costing approximately 5,000 to 10,000 RMB ($700–$1,400 USD) per session.

For patients evaluating costs across different specialties, our Ovarian Cancer Treatment in China: 2026 Cost & Care Guide offers parallel insights into gynecological oncology pricing.

Patients should budget $2,600 to $4,400 monthly for living expenses in a Tier-1 city like Guangzhou, Beijing, or Shanghai. Securing a serviced apartment is essential for managing the outpatient logistics of continuous chemotherapy or immunotherapy cycles.

Gastric cancer treatment is not a brief visit. Depending on the care plan, patients may need to stay for several months to complete multiple cycles of systemic therapy and undergo follow-up imaging to assess tumor response.

Managing Outpatient Care Unlike surgery, which requires an extended inpatient stay, most targeted therapies and immunotherapies are administered in an outpatient infusion center. Families must rent a serviced apartment near the hospital to provide a comfortable, hygienic environment for the patient to rest between cycles. Having a fully equipped kitchen is also vital, as patients undergoing systemic therapy often experience nausea or altered taste, requiring highly customized, easily digestible meals to maintain their nutritional status.

Visas and Daily Logistics International patients typically enter China on an M (Business/Medical) or S2 visa, requiring an official invitation letter from the destination hospital's international department. Monthly budgets covering a serviced apartment, groceries, and local transport average roughly 19,000 to 32,000 RMB.

Cross-border care requires strict medical record management. Patients must secure complete, translated copies of infusion logs, pathology slides, and biomarker reports to ensure a safe transition back to their local oncology team.

The most significant risk of international medical travel is the fragmentation of care. Gastric cancer requires continuous oncological follow-up and monitoring for delayed immune-related adverse events (irAEs) from PD-1 inhibitors.

If you are prescribed a Chinese-exclusive drug like RC48, you must consult with your home oncologist beforehand to determine if an FDA-approved alternative can be seamlessly substituted upon your return. Furthermore, always demand written, itemized quotes from the hospital's international department to avoid financial surprises, and rely only on professional medical interpreters rather than informal translators.

---

Organizing cross-border medical care requires precise planning, from securing the right specialist to managing complex medical translations and visa logistics. Ask China Medical provides professional, evidence-aware guidance to help international patients navigate China's healthcare system safely and efficiently.

If you are researching gastric cancer targeted therapies, evaluating clinical trials in Guangzhou, or preparing records for a second opinion, our team is here to make your next step clearer. Contact Ask China Medical today to learn how we can support your medical journey.